ArticleEuropean journal of neurology2025
Signs of Intracranial Hypertension in Chronic Inflammatory Polyradiculoneuropathies-A Cross Sectional Cohort Study.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Case report: Unilateral optic atrophy and intracranial hypertension in anti-NF155 nodopathy: a case managed with sequential efgartigimod and rituximab.Frontiers in immunology · 2026Article
- Signs of Intracranial Hypertension in Chronic Inflammatory Polyradiculoneuropathies-A Cross Sectional Cohort Study.European journal of neurology · 2026Article
- Signs of Intracranial Hypertension in Chronic Inflammatory Polyradiculoneuropathies-A Cross Sectional Cohort Study.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory polyradiculoneuropathy (IPN) has been associated with intracranial hypertension (IH) in various case reports, suggesting a potential link between the two conditions. However, the prevalence of IH in patients with IPN has not been addressed by prospective studies.
methodsIn this cross-sectional prospective study, we prospectively screened consecutive patients with chronic IPN for the presence of clinical and paraclinical signs of IH (fundoscopy, perimetry, optical coherence tomography, ultrasonography) between August 31, 2021, and December 31, 2023.
resultsOf 27 patients included (median age: 61.0 years [IQR 22.0]; 30.8% female; median time since diagnosis: 49.5 months [IQR 42.0]), ten patients (37.0%) with IPN had sonographic evidence of IH (IPN + IH), with 40% reporting symptoms of IH. Compared to patients without signs of IH, IPN + IH were younger (40.5 years [24.0] vs. 63.0 years [10.0]) and had higher CSF total protein (67.7 mg/dL [57.6] vs. 56.1 mg/dL [26.7]). However, IPN + IH did not have higher BMI (24.1 [5.2] vs. 26.0 [3.8]) or female predominance (33.3% vs. 29.4%). DISCUSSION: Signs of IH seem to be a common feature in IPN, indicating a likely association. The demographic and clinical profile of IPN + IH patients differs from that of idiopathic IH, suggesting that IH in IPN is likely secondary and may be linked to elevated CSF protein. Given that the majority of patients were asymptomatic and that the specificity of IH symptoms remains low, routine screening for subclinical IH signs may be warranted in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.